IR Notice
Dear Investors, This is John Rim, CEO of Samsung Biologics.
Key Hightlights
- Record High Quarterly Earnings
- Revenue: KRW 450.7B (YoY +64%) Operating Profit KRW 167 4B (YOY +196%)
- CMO Business Execution
- CMO contracts with Global Big Pharma including Roche and MSD
- CDO Development Platform
- New Technology Platform for Client Success With S-CellerateTM (Sep. 2021)
- ESG(Environmental, Social, Governance
- Climate Risk Management 'Frontier 1.5D Project' as part of 2050 Carbon Neutral Initiative
Today Samsung Biologics announced another record-high quarterly financial results Despite higher worldwide uncertainties than ever due to the prolonged COVID-19 pandemic, Samsung Biologics continues to provide a stable supply of pharmaceutical products to our valued clients and receive global regulatory approvals, enabled by strong operational excellence while maintaining a safe work environment for our employees. Thanks to these efforts along with a near-full operation of all three plants, Samsung Biologics achieved an outstanding, record-high third quarter earnings of 450.7 billion won in revenue and 167.4 billion won in operating profit, reflecting an increase of 176.1 billion won and 110.9 billion won compared to the same period last year, respectively. Samsung Biologics launched a technology enabled CDO Platform 'S-Cellerate In addition to recording a strong cumulative backlog of $7.1 billion in signed contracts with large pharmaceutical companies such as Roche and MSD this quarter, Samsung Biologics also successfully launched a CDO Platform 'S-Cellerate TM' in September.
Through this technology-enabled platform, clients are able to significantly shorten the biopharmaceutical development period while reducing R&D costs from cell line development to IND submission, and Process Characterization (PC) to Biologics License Application (BLA). Our CDO business has achieved 82 signed contracts within three years since its market entry in 2018, and provides end-to-end services for the development of new drugs throughout the entire process, from preclinical to clinical trials and commercial production. Enhancing ESG (Environmental, Social, Governance) Performance In addition, we are operating a committee to proactively respond to climate change and to manage risks associated with energy use. Through the systematic operation of our ESG management system, we continue to monitor the impact of climate change on our business activities while establishing a goal of reducing greenhouse gas units based on production. In September, we announced our participation in the Frontier -1.5D initiative to develop a climate risk management model in a collaborative effort with industrial sector representatives and the financial Supervisory Service and fulfill our responsibility as a leading company in the global CDMO market. We appreciate your continued support and interest in Samsung Biologics. We will continue to devote ourselves to creating a better future for humanity and enriching human lives through innovation and advanced technology. Thank you
Sincerely, John Rim President and CEO, Samsung Biologics
Dear Investors, This is John Rim, CEO of Samsung Biologics.
Key Hightlights
- Record High Quarterly Earnings
- Revenue: KRW 450.7B (YoY +64%) Operating Profit KRW 167 4B (YOY +196%)
- CMO Business Execution
- CMO contracts with Global Big Pharma including Roche and MSD
- CDO Development Platform
- New Technology Platform for Client Success With S-CellerateTM (Sep. 2021)
- ESG(Environmental, Social, Governance
- Climate Risk Management 'Frontier 1.5D Project' as part of 2050 Carbon Neutral Initiative
Today Samsung Biologics announced another record-high quarterly financial results Despite higher worldwide uncertainties than ever due to the prolonged COVID-19 pandemic, Samsung Biologics continues to provide a stable supply of pharmaceutical products to our valued clients and receive global regulatory approvals, enabled by strong operational excellence while maintaining a safe work environment for our employees. Thanks to these efforts along with a near-full operation of all three plants, Samsung Biologics achieved an outstanding, record-high third quarter earnings of 450.7 billion won in revenue and 167.4 billion won in operating profit, reflecting an increase of 176.1 billion won and 110.9 billion won compared to the same period last year, respectively. Samsung Biologics launched a technology enabled CDO Platform 'S-Cellerate In addition to recording a strong cumulative backlog of $7.1 billion in signed contracts with large pharmaceutical companies such as Roche and MSD this quarter, Samsung Biologics also successfully launched a CDO Platform 'S-Cellerate TM' in September.
Through this technology-enabled platform, clients are able to significantly shorten the biopharmaceutical development period while reducing R&D costs from cell line development to IND submission, and Process Characterization (PC) to Biologics License Application (BLA). Our CDO business has achieved 82 signed contracts within three years since its market entry in 2018, and provides end-to-end services for the development of new drugs throughout the entire process, from preclinical to clinical trials and commercial production. Enhancing ESG (Environmental, Social, Governance) Performance In addition, we are operating a committee to proactively respond to climate change and to manage risks associated with energy use. Through the systematic operation of our ESG management system, we continue to monitor the impact of climate change on our business activities while establishing a goal of reducing greenhouse gas units based on production. In September, we announced our participation in the Frontier -1.5D initiative to develop a climate risk management model in a collaborative effort with industrial sector representatives and the financial Supervisory Service and fulfill our responsibility as a leading company in the global CDMO market. We appreciate your continued support and interest in Samsung Biologics. We will continue to devote ourselves to creating a better future for humanity and enriching human lives through innovation and advanced technology. Thank you
Sincerely, John Rim President and CEO, Samsung Biologics